IIS Aragón. S. de Cirugía General y del Ap. Digestivo, Hospital Universitario Miguel Servet, Zaragoza, España.
S. de Cirugía General y del Ap. Digestivo, Hospital Universitario Miguel Servet, Zaragoza, España.
Cir Esp (Engl Ed). 2021 Feb;99(2):132-139. doi: 10.1016/j.ciresp.2020.04.024. Epub 2020 May 31.
In early breast cancer (EBC), a single dose of intraoperative radiotherapy (IORT) might be an option to standard whole breast radiotherapy (WBRT). However, there is no consensus about its use and clinical results.
to analyse the morbidity and oncological outcomes of IORT as monotherapy in EBC.
A single centre observational analytic study was performed. A prospective IORT cohort (2015-17) and a retrospective WBRT cohort (2012-17) were selected following the same criteria: ≥ 45 y.o., invasive ductal carcinoma or variants, radiological tumour size ≤ 3 cm, positive oestrogenic receptors, negative HER2, cN0; exclusion criteria: lymphovascular invasion, multicentricity/multifocality, BRCA mutation and neoadjuvant therapy. Clinical, histological, surgical, oncological characteristics and complications were collected.
A total of 425 cases were selected: 217 in IORT cohort and 208 in WBRT cohort. Average age in IORT and WBRT groups was 67±9.5 and 64.8 ± 9.9 y.o. respectively (p = 0.01). ASA 3 risk score patients were 17.7% in IORT and 24 cases in WBRT (p = 0.027). There were no differences in histological results or tumoral stage. Average follow up was 24.4 ± 8 months in IORT and 50.5 ± 18 months in WBRT (p < 0.001). No differences were detected in local recurrence, metastases or mortality. Complications that required reintervention or hospitalization were similar in both groups. A total of 3 and 14 cases developed early severe dermatitis in IORT and WBRT groups respectively (p = 0.01).
IORT as monotherapy in selected patients with EBC stands for an alternative option versus WBRT. It seems especially useful in advanced-age patients with severe comorbidities. IORT associates lesser early severe dermatitis.
在早期乳腺癌(EBC)中,单次术中放疗(IORT)可能是标准全乳放疗(WBRT)的一种选择。然而,其使用和临床结果尚无共识。
分析 IORT 作为 EBC 单一疗法的发病率和肿瘤学结果。
进行了一项单中心观察性分析研究。选择了一个前瞻性 IORT 队列(2015-17 年)和一个回顾性 WBRT 队列(2012-17 年),遵循相同的标准:≥45 岁,浸润性导管癌或变异型,影像学肿瘤大小≤3cm,雌激素受体阳性,HER2 阴性,cN0;排除标准:淋巴血管侵犯,多中心/多灶性,BRCA 突变和新辅助治疗。收集了临床、组织学、手术、肿瘤学特征和并发症。
共选择了 425 例患者:IORT 队列 217 例,WBRT 队列 208 例。IORT 和 WBRT 组的平均年龄分别为 67±9.5 和 64.8±9.9 岁(p=0.01)。IORT 组中 ASA 3 风险评分患者为 17.7%,WBRT 组为 24 例(p=0.027)。组织学结果或肿瘤分期无差异。IORT 的平均随访时间为 24.4±8 个月,WBRT 为 50.5±18 个月(p<0.001)。局部复发、转移或死亡无差异。两组需要再次干预或住院治疗的并发症相似。IORT 和 WBRT 组分别有 3 例和 14 例发生早期严重皮炎(p=0.01)。
IORT 作为 EBC 患者的单一疗法,是 WBRT 的一种替代选择。它似乎对患有严重合并症的老年患者特别有用。IORT 相关的早期严重皮炎较少。